Drug Review: Ibrutinib

Abstract Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of medical and paediatric oncology 2020-05, Vol.41 (3), p.383-392
Main Author: Karunakaran, Parathan
Format: Article
Language:English
Subjects:
Apixaban
B cells
Drug Review
Ibrutinib
Infection
Inhibitor drugs
Leukemia
Lymphomas
Targeted cancer therapy
Tumor proteins
Venetoclax
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c479i-738f8cc7e8169e555fe25e40e523cefff0a6cc519ca6029fd1941a2262920db93
container_end_page 392
container_issue 3
container_start_page 383
container_title Indian journal of medical and paediatric oncology
container_volume 41
creator Karunakaran, Parathan
description Abstract Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refractory to conventional chemoimmunotherapy. This small-molecule inhibitor has shown efficacy in this difficult-to-treat subset – those with del(17p)/TP53-mutated CLL. Its immunomodulatory properties make it an excellent choice for combining with other immunotherapeutic agents such as venetoclax. The drug is not without drawbacks. The need for indefinite therapy and the presence of adverse effects such as infection, bleeding, hypertension, and arrhythmia temper our enthusiasm for this versatile drug. But overall, ibrutinib's favorable risk profile and lack of myelosuppression make it an ideal therapy for the elderly and those with multiple comorbidities.
doi_str_mv 10.4103/ijmpo.ijmpo_36_20
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2532578264</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A628269054</galeid><sourcerecordid>A628269054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479i-738f8cc7e8169e555fe25e40e523cefff0a6cc519ca6029fd1941a2262920db93</originalsourceid><addsrcrecordid>eNp1kV1LwzAYhYsoOKe3gncDwbvOfDRt492YX4PBQPQ6ZNmbLVvbzKS1-O_tVmUbOAJJCM85bzgnCG4w6kcY0XuzzNe2v90FjQVBJ0EH8YSFBBN-ur3jkKUMnwcX3i8RogzHaSe4fnTVvPcGXwbqh95o6qrSFGZ6GZxpmXm4-j27wcfz0_vwNRxPXkbDwThUUcJNmNBUp0olkOKYA2NMA2EQIWCEKtBaIxkrxTBXMkaE6xnmEZaExIQTNJty2g1uW9-1s58V-FIsbeWKZqQgjBKWpCSOdtRcZiBMoW3ppMqNV2IQkwbhiG2o_j9Us2aQG2UL0KZ5PxDc7QkWILNy4W3WJGALfwjiFlTOeu9Ai7UzuXTfAiOxiV-0we_F32gmraa2WQnOr7KqBidymK0KWx8XCppSsSlFuG0p4q-TxhG1juXCQA67pI5_4gf1YqTl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2532578264</pqid></control><display><type>article</type><title>Drug Review: Ibrutinib</title><source>Publicly Available Content Database</source><creator>Karunakaran, Parathan</creator><creatorcontrib>Karunakaran, Parathan</creatorcontrib><description>Abstract Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refractory to conventional chemoimmunotherapy. This small-molecule inhibitor has shown efficacy in this difficult-to-treat subset – those with del(17p)/TP53-mutated CLL. Its immunomodulatory properties make it an excellent choice for combining with other immunotherapeutic agents such as venetoclax. The drug is not without drawbacks. The need for indefinite therapy and the presence of adverse effects such as infection, bleeding, hypertension, and arrhythmia temper our enthusiasm for this versatile drug. But overall, ibrutinib's favorable risk profile and lack of myelosuppression make it an ideal therapy for the elderly and those with multiple comorbidities.</description><identifier>ISSN: 0971-5851</identifier><identifier>EISSN: 0975-2129</identifier><identifier>DOI: 10.4103/ijmpo.ijmpo_36_20</identifier><language>eng</language><publisher>A-12, 2nd Floor, Sector 2, Noida-201301 UP, India: Thieme Medical and Scientific Publishers Pvt. Ltd</publisher><subject>Apixaban ; B cells ; Drug Review ; Ibrutinib ; Infection ; Inhibitor drugs ; Leukemia ; Lymphomas ; Targeted cancer therapy ; Tumor proteins ; Venetoclax</subject><ispartof>Indian journal of medical and paediatric oncology, 2020-05, Vol.41 (3), p.383-392</ispartof><rights>Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)</rights><rights>COPYRIGHT 2020 Medknow Publications and Media Pvt. Ltd.</rights><rights>2020. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c479i-738f8cc7e8169e555fe25e40e523cefff0a6cc519ca6029fd1941a2262920db93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2532578264?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590</link.rule.ids></links><search><creatorcontrib>Karunakaran, Parathan</creatorcontrib><title>Drug Review: Ibrutinib</title><title>Indian journal of medical and paediatric oncology</title><addtitle>Indian J Med Paediatr Oncol</addtitle><description>Abstract Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refractory to conventional chemoimmunotherapy. This small-molecule inhibitor has shown efficacy in this difficult-to-treat subset – those with del(17p)/TP53-mutated CLL. Its immunomodulatory properties make it an excellent choice for combining with other immunotherapeutic agents such as venetoclax. The drug is not without drawbacks. The need for indefinite therapy and the presence of adverse effects such as infection, bleeding, hypertension, and arrhythmia temper our enthusiasm for this versatile drug. But overall, ibrutinib's favorable risk profile and lack of myelosuppression make it an ideal therapy for the elderly and those with multiple comorbidities.</description><subject>Apixaban</subject><subject>B cells</subject><subject>Drug Review</subject><subject>Ibrutinib</subject><subject>Infection</subject><subject>Inhibitor drugs</subject><subject>Leukemia</subject><subject>Lymphomas</subject><subject>Targeted cancer therapy</subject><subject>Tumor proteins</subject><subject>Venetoclax</subject><issn>0971-5851</issn><issn>0975-2129</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>0U6</sourceid><sourceid>PIMPY</sourceid><recordid>eNp1kV1LwzAYhYsoOKe3gncDwbvOfDRt492YX4PBQPQ6ZNmbLVvbzKS1-O_tVmUbOAJJCM85bzgnCG4w6kcY0XuzzNe2v90FjQVBJ0EH8YSFBBN-ur3jkKUMnwcX3i8RogzHaSe4fnTVvPcGXwbqh95o6qrSFGZ6GZxpmXm4-j27wcfz0_vwNRxPXkbDwThUUcJNmNBUp0olkOKYA2NMA2EQIWCEKtBaIxkrxTBXMkaE6xnmEZaExIQTNJty2g1uW9-1s58V-FIsbeWKZqQgjBKWpCSOdtRcZiBMoW3ppMqNV2IQkwbhiG2o_j9Us2aQG2UL0KZ5PxDc7QkWILNy4W3WJGALfwjiFlTOeu9Ai7UzuXTfAiOxiV-0we_F32gmraa2WQnOr7KqBidymK0KWx8XCppSsSlFuG0p4q-TxhG1juXCQA67pI5_4gf1YqTl</recordid><startdate>202005</startdate><enddate>202005</enddate><creator>Karunakaran, Parathan</creator><general>Thieme Medical and Scientific Publishers Pvt. Ltd</general><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Medknow Publications &amp; Media Pvt. Ltd</general><scope>0U6</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PADUT</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>202005</creationdate><title>Drug Review: Ibrutinib</title><author>Karunakaran, Parathan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479i-738f8cc7e8169e555fe25e40e523cefff0a6cc519ca6029fd1941a2262920db93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Apixaban</topic><topic>B cells</topic><topic>Drug Review</topic><topic>Ibrutinib</topic><topic>Infection</topic><topic>Inhibitor drugs</topic><topic>Leukemia</topic><topic>Lymphomas</topic><topic>Targeted cancer therapy</topic><topic>Tumor proteins</topic><topic>Venetoclax</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karunakaran, Parathan</creatorcontrib><collection>Thieme Connect Journals Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Research Library China</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Indian journal of medical and paediatric oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karunakaran, Parathan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug Review: Ibrutinib</atitle><jtitle>Indian journal of medical and paediatric oncology</jtitle><addtitle>Indian J Med Paediatr Oncol</addtitle><date>2020-05</date><risdate>2020</risdate><volume>41</volume><issue>3</issue><spage>383</spage><epage>392</epage><pages>383-392</pages><issn>0971-5851</issn><eissn>0975-2129</eissn><abstract>Abstract Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refractory to conventional chemoimmunotherapy. This small-molecule inhibitor has shown efficacy in this difficult-to-treat subset – those with del(17p)/TP53-mutated CLL. Its immunomodulatory properties make it an excellent choice for combining with other immunotherapeutic agents such as venetoclax. The drug is not without drawbacks. The need for indefinite therapy and the presence of adverse effects such as infection, bleeding, hypertension, and arrhythmia temper our enthusiasm for this versatile drug. But overall, ibrutinib's favorable risk profile and lack of myelosuppression make it an ideal therapy for the elderly and those with multiple comorbidities.</abstract><cop>A-12, 2nd Floor, Sector 2, Noida-201301 UP, India</cop><pub>Thieme Medical and Scientific Publishers Pvt. Ltd</pub><doi>10.4103/ijmpo.ijmpo_36_20</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0971-5851
ispartof Indian journal of medical and paediatric oncology, 2020-05, Vol.41 (3), p.383-392
issn 0971-5851
0975-2129
language eng
recordid cdi_proquest_journals_2532578264
source Publicly Available Content Database
subjects Apixaban
B cells
Drug Review
Ibrutinib
Infection
Inhibitor drugs
Leukemia
Lymphomas
Targeted cancer therapy
Tumor proteins
Venetoclax
title Drug Review: Ibrutinib
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A35%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20Review:%20Ibrutinib&rft.jtitle=Indian%20journal%20of%20medical%20and%20paediatric%20oncology&rft.au=Karunakaran,%20Parathan&rft.date=2020-05&rft.volume=41&rft.issue=3&rft.spage=383&rft.epage=392&rft.pages=383-392&rft.issn=0971-5851&rft.eissn=0975-2129&rft_id=info:doi/10.4103/ijmpo.ijmpo_36_20&rft_dat=%3Cgale_proqu%3EA628269054%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c479i-738f8cc7e8169e555fe25e40e523cefff0a6cc519ca6029fd1941a2262920db93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2532578264&rft_id=info:pmid/&rft_galeid=A628269054&rfr_iscdi=true